Changyao Group(300391)

Search documents
长药控股(300391) - 2025 Q1 - 季度财报(更正)
2025-08-25 11:40
[Key Disclosure Information](index=1&type=section&id=Key%20Disclosure%20Information) The report confirms the board and management's assurance of the quarterly report's accuracy and completeness, noting it remains unaudited - The board of directors, supervisory board, and senior management guarantee the truthfulness, accuracy, and completeness of the quarterly report, free from false records, misleading statements, or major omissions, assuming individual and joint legal responsibility[3](index=3&type=chunk) - The company's principal, chief financial officer, and head of accounting department declare the financial information in the quarterly report is true, accurate, and complete[3](index=3&type=chunk) - This first quarter report is unaudited[4](index=4&type=chunk)[41](index=41&type=chunk) [I. Key Financial Data](index=2&type=section&id=I.%20Key%20Financial%20Data) The company's Q1 2025 financial performance significantly deteriorated, with revenue down **22.50%**, net loss attributable to shareholders widening by **28.01%**, and operating cash flow plummeting by **118.90%**; shareholder equity remained negative and further declined [ (I) Key Accounting Data and Financial Indicators](index=2&type=section&id=%28I%29%20Key%20Accounting%20Data%20and%20Financial%20Indicators) In Q1 2025, revenue and net profit significantly declined, operating cash flow worsened, EPS loss expanded, total assets slightly grew, but shareholder equity remained negative and further decreased Key Accounting Data and Financial Indicators | Indicator | Current Period | Prior Year Period | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue (RMB) | 45,795,675.76 | 59,091,762.31 | -22.50% | | Net Profit Attributable to Shareholders (RMB) | -60,812,317.13 | -47,505,902.27 | -28.01% | | Net Profit Attributable to Shareholders Excluding Non-recurring Items (RMB) | -62,639,023.43 | -45,659,634.61 | -37.19% | | Net Cash Flow from Operating Activities (RMB) | -71,835,780.49 | -32,816,721.93 | -118.90% | | Basic Earnings Per Share (RMB/share) | -0.1736 | -0.1356 | -28.02% | | Diluted Earnings Per Share (RMB/share) | -0.1736 | -0.1356 | -28.02% | | Weighted Average Return on Net Assets | -13.13% | -27.72% | 14.59% | | **Period-End Indicators** | **Current Period-End** | **Prior Year-End** | **Change from Prior Year-End (%)** | | Total Assets (RMB) | 2,042,496,723.36 | 1,995,717,642.12 | 2.34% | | Shareholders' Equity Attributable to Listed Company (RMB) | -493,652,976.34 | -432,840,659.21 | -14.05% | [ (II) Non-recurring Gains and Losses Items and Amounts](index=2&type=section&id=%28II%29%20Non-recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) Total non-recurring gains and losses for the period amounted to **RMB 1,826,706.30**, primarily from fair value changes in financial assets and debt restructuring, partially offsetting non-current asset disposal losses and non-operating expenses Non-recurring Gains and Losses Items and Amounts | Item | Amount for Current Period (RMB) | Description | | :--- | :--- | :--- | | Gains/Losses on Disposal of Non-current Assets | -101,726.14 | | | Government Grants Included in Current Profit/Loss | 315,367.93 | | | Gains/Losses from Fair Value Changes of Financial Assets and Liabilities Held by Non-financial Enterprises and Disposal of Financial Assets and Liabilities | 2,200,000.00 | | | Debt Restructuring Gains/Losses | 700,000.00 | | | Other Non-operating Income and Expenses Apart from the Above | -224,147.09 | | | Impact on Minority Interests (After Tax) | 1,062,788.40 | | | **Total** | **1,826,706.30** | -- | - The company has not classified any non-recurring gains and losses items listed in 'Interpretive Announcement No. 1 on Information Disclosure by Companies Issuing Securities to the Public—Non-recurring Gains and Losses' as recurring items[7](index=7&type=chunk)[8](index=8&type=chunk) [ (III) Changes and Reasons for Key Accounting Data and Financial Indicators](index=3&type=section&id=%28III%29%20Changes%20and%20Reasons%20for%20Key%20Accounting%20Data%20and%20Financial%20Indicators) Multiple financial indicators saw significant year-over-year changes, including a **52.27%** rise in provisions, **22.50%** revenue decline, **181.54%** surge in financial expenses, **118.90%** deterioration in operating cash flow, and **117.58%** increase in financing cash flow Changes and Reasons for Key Accounting Data and Financial Indicators | Item | Current Period (RMB) | Prior Year Period (RMB) | YoY Change (%) | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Provisions | 45,808,696.12 | 30,084,303.04 | 52.27% | Due to increase in pending lawsuits | | Operating Revenue | 45,795,675.76 | 59,091,762.31 | -22.50% | Due to year-over-year decrease in pharmaceutical sector revenue | | Operating Cost | 47,500,988.09 | 54,604,638.79 | -13.01% | Due to year-over-year decrease in pharmaceutical sector revenue | | Financial Expenses | 34,973,280.67 | 12,422,196.09 | 181.54% | Due to interest accrued for lawsuits | | Credit Impairment Losses | -31,953,818.21 | -47,021,483.23 | 32.04% | Due to year-over-year decrease in allowance for doubtful accounts | | Non-operating Expenses | 289,356.56 | 3,692,085.55 | -92.16% | Due to compensation expenses arising from product quality issues in the prior year period | | Net Cash Flow from Operating Activities | -71,835,780.49 | -32,816,721.93 | -118.90% | Due to decrease in sales collections | | Net Cash Flow from Financing Activities | 68,545,138.96 | 31,502,907.79 | 117.58% | Due to increase in borrowings | [II. Shareholder Information](index=3&type=section&id=II.%20Shareholder%20Information) As of the reporting period end, the company had **20,224** common shareholders; the top ten shareholders' holdings show Changxing Shengshifenghua Business Co., Ltd. as the largest shareholder with **10.11%**, most of its shares pledged, and the company is unaware of any related party relationships or concerted actions among shareholders [ (I) Total Number of Common Shareholders and Top Ten Shareholders' Holdings](index=3&type=section&id=%28I%29%20Total%20Number%20of%20Common%20Shareholders%20and%20Top%20Ten%20Shareholders%27%20Holdings) At the end of the reporting period, there were **20,224** common shareholders and no preferred shareholders with restored voting rights; among the top ten, Changxing Shengshifenghua Business Co., Ltd. was the largest shareholder with **10.11%**, holding **21,002,800** pledged shares, while Shouguang Kangyue Investment Co., Ltd. had **9,500,000** frozen shares - The total number of common shareholders at the end of the reporting period was **20,224**, and the total number of preferred shareholders with restored voting rights was **0** at the end of the reporting period[12](index=12&type=chunk) Top Ten Common Shareholders' Holdings | Shareholder Name | Shareholder Nature | Holding Ratio (%) | Number of Shares (shares) | Pledged, Marked, or Frozen Status | | :--- | :--- | :--- | :--- | :--- | | Changxing Shengshifenghua Business Co., Ltd. | Domestic Non-state-owned Legal Person | 10.11% | 35,423,600.00 | Pledged 21,002,800.00 | | Shanghai Yucong Asset Management Co., Ltd. - Yucong Tianshun No. 2 Private Securities Investment Fund | Other | 5.99% | 21,000,000.00 | Not Applicable 0.00 | | Liu Lili | Domestic Natural Person | 5.05% | 17,681,253.00 | Not Applicable 0.00 | | Shouguang Kangyue Investment Co., Ltd. | Domestic Non-state-owned Legal Person | 3.46% | 12,114,547.00 | Frozen 9,500,000.00 | | Xu Guifang | Domestic Natural Person | 0.78% | 2,732,600.00 | Not Applicable 0.00 | | Wang Fugen | Domestic Natural Person | 0.70% | 2,461,250.00 | Not Applicable 0.00 | | Li Yufang | Domestic Natural Person | 0.54% | 1,900,005.00 | Not Applicable 0.00 | | Ma Junping | Domestic Natural Person | 0.53% | 1,852,450.00 | Not Applicable 0.00 | | Chen Naping | Domestic Natural Person | 0.52% | 1,836,450.00 | Not Applicable 0.00 | | Hao Kai | Domestic Natural Person | 0.52% | 1,808,050.00 | Not Applicable 0.00 | - The company is unaware of any associated relationships among shareholders or whether they constitute concerted parties as defined by the "Measures for the Administration of the Acquisition of Listed Companies"[13](index=13&type=chunk) - Shareholder Hao Kai holds **800,000** shares through a common securities account and **1,008,050** shares through a Zheshang Securities Co., Ltd. client credit trading guarantee securities account, totaling **1,808,050** shares[13](index=13&type=chunk) [ (II) Preferred Shareholder Information](index=4&type=section&id=%28II%29%20Preferred%20Shareholder%20Information) The company has no preferred shareholders - The company has no preferred shareholders[14](index=14&type=chunk) [ (III) Changes in Restricted Shares](index=4&type=section&id=%28III%29%20Changes%20in%20Restricted%20Shares) There were no changes in the company's restricted shares - There were no changes in the company's restricted shares[14](index=14&type=chunk) [III. Other Significant Matters](index=4&type=section&id=III.%20Other%20Significant%20Matters) The company faces severe going concern uncertainties, including negative net assets, huge accumulated losses, significant revenue decline, numerous overdue debts, and frozen bank accounts; additionally, the company has entered pre-reorganization, its subsidiaries have been ruled for bankruptcy reorganization, posing significant risks of reorganization failure and stock delisting [ (I) Risk Warning for Significant Uncertainties Related to Going Concern in the 2024 Annual Audit Report](index=4&type=section&id=%28I%292024%20Annual%20Audit%20Report%20Risk%20Warning%20for%20Significant%20Uncertainties%20Related%20to%20Going%20Concern) As of year-end 2024, the company had negative net assets, substantial accumulated losses, three consecutive years of negative operating cash flow, and severe revenue decline; numerous overdue debts led to frozen bank accounts and seized assets, with subsidiaries entering bankruptcy reorganization, indicating significant going concern uncertainties - As of December 31, 2024, the company's consolidated financial statements showed net assets attributable to the parent company of **-RMB 432,840,659.21**, undistributed profits of **-RMB 1,589,707,417.48**, and net profit attributable to parent company shareholders of **-RMB 627,961,728.50** for 2024[14](index=14&type=chunk) - The company's net operating cash flow has been negative for **3** consecutive years, with a huge accumulated loss[14](index=14&type=chunk) - The company's operating revenue has severely declined from **RMB 1.615 billion** in 2022 and **RMB 1.198 billion** in 2023 to **RMB 112 million** in 2024[14](index=14&type=chunk) - Numerous overdue debts have led to lawsuits from some creditors, resulting in a large number of frozen bank accounts and seized assets[14](index=14&type=chunk) - On January 20, 2025, the Shiyan Intermediate People's Court of Hubei Province decided to initiate pre-reorganization for Changyao Holdings; on March 10, 2025, the Shiyan Intermediate People's Court ruled for the bankruptcy reorganization of subsidiary Hubei Changjiang Star Pharmaceutical Co., Ltd.; on March 27, 2025, the Shiyan Intermediate People's Court ruled for the consolidated reorganization of seven subsidiaries[15](index=15&type=chunk) - The aforementioned matters or circumstances indicate significant uncertainties regarding Changyao Holdings' ability to continue as a going concern without major changes[16](index=16&type=chunk) [ (II) Risk of Reorganization Failure](index=4&type=section&id=%28II%29%20Risk%20of%20Reorganization%20Failure) The company has entered pre-reorganization, but its formal entry into reorganization remains uncertain; if the court accepts the reorganization application, the company's stock will be subject to delisting risk warnings, and if reorganization fails, the company may be declared bankrupt and liquidated, facing the risk of stock delisting - The company entered the pre-reorganization phase on January 20, 2025, but whether it can formally enter the reorganization process remains uncertain[18](index=18&type=chunk) - If the court rules to accept the company's reorganization application, the company's stock trading will be subject to delisting risk warnings[18](index=18&type=chunk) - Even if the court formally accepts the reorganization application, there is still a risk of being declared bankrupt and liquidated due to reorganization failure, which may lead to the company's stock facing the risk of delisting[18](index=18&type=chunk) [ (III) Risk of Stock Delisting](index=5&type=section&id=%28III%29%20Risk%20of%20Stock%20Delisting) The company's stock has been subject to delisting risk warnings since April 22, 2025; according to the "Shenzhen Stock Exchange ChiNext Stock Listing Rules," if the company's 2025 audited total profit, net profit, or net profit after non-recurring items is negative and operating revenue after deduction is below **RMB 100 million**, or if net assets at year-end are negative, or if the financial report receives a non-standard audit opinion, the company's stock will face delisting risk - The company's stock trading has been subject to delisting risk warnings since April 22, 2025[19](index=19&type=chunk) - If the company's 2025 audited total profit, net profit, or net profit after deducting non-recurring gains and losses is negative, and the operating revenue after deduction is below **RMB 100 million**, the Shenzhen Stock Exchange will decide to terminate the company's stock listing[19](index=19&type=chunk)[27](index=27&type=chunk) - If the company's 2025 audited net assets at year-end are negative, the Shenzhen Stock Exchange will decide to terminate the company's stock listing[20](index=20&type=chunk)[27](index=27&type=chunk) - If the company's 2025 financial accounting report receives a qualified, adverse, or disclaimer of opinion audit report, the Shenzhen Stock Exchange will decide to terminate the company's stock listing[21](index=21&type=chunk)[27](index=27&type=chunk) - Investors are kindly requested to pay attention to investment risks[28](index=28&type=chunk) [IV. Quarterly Financial Statements](index=5&type=section&id=IV.%20Quarterly%20Financial%20Statements) This section provides the company's consolidated balance sheet, consolidated income statement, and consolidated cash flow statement for Q1 2025, detailing the financial position, operating results, and cash flows at the end of the reporting period; the company did not adopt new accounting standards for the first time in this period, and the quarterly report is unaudited [ (I) Financial Statements](index=5&type=section&id=%28I%29%20Financial%20Statements) Includes the consolidated balance sheet, consolidated income statement, and consolidated cash flow statement, reflecting the company's assets, liabilities, owner's equity, revenue, expenses, profit, and cash inflows and outflows for Q1 2025 [1. Consolidated Balance Sheet](index=5&type=section&id=1.%20Consolidated%20Balance%20Sheet) As of March 31, 2025, the company's total assets were **RMB 2.042 billion**, a **2.34%** increase from the beginning of the period; total current assets were **RMB 1.185 billion**, and total non-current assets were **RMB 858 million**; total liabilities were **RMB 2.553 billion**, with current liabilities at **RMB 2.045 billion** and non-current liabilities at **RMB 508 million**; owner's equity attributable to the parent company was **-RMB 494 million**, minority interests were **-RMB 17 million**, and total owner's equity was **-RMB 511 million**, indicating persistently negative net assets Consolidated Balance Sheet | Item | Period-End Balance (RMB) | Period-Beginning Balance (RMB) | | :--- | :--- | :--- | | **Assets** | | | | Total Current Assets | 1,184,629,835.39 | 1,129,357,419.11 | | Total Non-current Assets | 857,866,887.97 | 866,360,223.01 | | **Total Assets** | **2,042,496,723.36** | **1,995,717,642.12** | | **Liabilities** | | | | Total Current Liabilities | 2,045,192,800.38 | 1,924,644,829.41 | | Total Non-current Liabilities | 508,055,500.27 | 492,427,835.02 | | **Total Liabilities** | **2,553,248,300.65** | **2,417,072,664.43** | | **Owner's Equity** | | | | Total Owner's Equity Attributable to Parent Company | -493,652,976.34 | -432,840,659.21 | | Minority Interests | -17,098,600.95 | 11,485,636.90 | | **Total Owner's Equity** | **-510,751,577.29** | **-421,355,022.31** | - Cash and cash equivalents at period-end amounted to **RMB 9,012,776.10**, while accounts receivable reached **RMB 1,023,063,349.86**[30](index=30&type=chunk)[31](index=31&type=chunk) - Other payables amounted to **RMB 1,324,188,274.25**, including interest payable of **RMB 12,738,377.66**[32](index=32&type=chunk) - Undistributed profits were **-RMB 1,650,519,734.61**, further deteriorating from the beginning of the period[32](index=32&type=chunk) [2. Consolidated Income Statement](index=7&type=section&id=2.%20Consolidated%20Income%20Statement) In Q1 2025, the company's total operating revenue was **RMB 45.80 million**, a **22.50%** year-over-year decrease; total operating costs were **RMB 106 million**, with financial expenses significantly increasing by **181.54%** year-over-year; the company reported a net loss of **RMB 89.40 million**, and net loss attributable to parent company owners was **RMB 60.81 million**, widening the loss compared to the prior year period Consolidated Income Statement | Item | Amount for Current Period (RMB) | Amount for Prior Period (RMB) | | :--- | :--- | :--- | | Total Operating Revenue | 45,795,675.76 | 59,091,762.31 | | Total Operating Costs | 106,127,907.23 | 89,749,307.79 | | Including: Operating Cost | 47,500,988.09 | 54,604,638.79 | | Selling Expenses | 2,939,791.68 | 5,103,682.48 | | Administrative Expenses | 19,053,546.04 | 16,085,180.97 | | Financial Expenses | 34,973,280.67 | 12,422,196.09 | | Credit Impairment Losses | -31,953,818.21 | -47,021,483.23 | | Operating Profit | -89,172,407.89 | -77,433,335.93 | | Total Profit | -89,396,554.98 | -81,120,269.42 | | Net Profit | -89,396,554.98 | -81,120,269.42 | | Net Profit Attributable to Parent Company Owners | -60,812,317.13 | -47,505,902.27 | | Basic Earnings Per Share | -0.1736 | -0.1356 | - Investment income for the current period was **RMB 2,900,000.00**, compared to **RMB 0** in the prior period[35](index=35&type=chunk) - Minority interest loss was **-RMB 28,584,237.85**, an improvement from **-RMB 33,614,367.15** in the prior period[36](index=36&type=chunk) [3. Consolidated Cash Flow Statement](index=9&type=section&id=3.%20Consolidated%20Cash%20Flow%20Statement) In Q1 2025, net cash flow from operating activities was **-RMB 71.84 million**, a **118.90%** year-over-year deterioration primarily due to reduced sales collections; net cash flow from investing activities turned positive to **RMB 1.17 million**, mainly from other cash received related to investing activities; net cash flow from financing activities was **RMB 68.55 million**, a **117.58%** year-over-year increase primarily due to increased borrowings; cash and cash equivalents balance at period-end was **RMB 3.29 million** Consolidated Cash Flow Statement | Item | Amount for Current Period (RMB) | Amount for Prior Period (RMB) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | -71,835,780.49 | -32,816,721.93 | | Net Cash Flow from Investing Activities | 1,174,560.80 | -2,690,657.00 | | Net Cash Flow from Financing Activities | 68,545,138.96 | 31,502,907.79 | | Net Increase in Cash and Cash Equivalents | -2,116,098.55 | -3,984,366.60 | | Cash and Cash Equivalents at Period-End | 3,289,786.32 | 2,316,745.24 | - Cash received from sales of goods and rendering of services for the current period was **RMB 39,130,032.28**, a year-over-year decrease of approximately **20.8%** from **RMB 49,400,392.01** in the prior period[38](index=38&type=chunk) - Cash paid for goods and services for the current period was **RMB 88,612,091.37**, a year-over-year increase of approximately **50.8%** from **RMB 58,777,551.13** in the prior period[39](index=39&type=chunk) - Other cash received related to investing activities was **RMB 1,320,000.00** for the current period, compared to **RMB 0** in the prior period[39](index=39&type=chunk) - Cash paid for debt repayment for the current period was **RMB 288,981.79**, a significant decrease from **RMB 16,548,619.51** in the prior period[40](index=40&type=chunk) [ (II) Adjustments for First-time Adoption of New Accounting Standards in 2025](index=11&type=section&id=%28II%29%20Adjustments%20for%20First-time%20Adoption%20of%20New%20Accounting%20Standards%20in%202025) The company did not adopt new accounting standards for the first time in 2025, thus no adjustments to the opening financial statements for the first year of adoption are required - The company did not adopt new accounting standards for the first time in 2025[41](index=41&type=chunk) [ (III) Audit Report](index=11&type=section&id=%28III%29%20Audit%20Report) The company's Q1 2025 report is unaudited - The company's first quarter report is unaudited[41](index=41&type=chunk)
*ST长药(300391) - 关于2025年第一季度财务报告会计差错更正的公告
2025-08-25 11:39
2、本次会计差错更正事项仅对公司2025年第一季度报告中合并利润表的相关 项目及指标有影响。 公司于2025年8月22日召开第六届董事会第二次会议,审议通过了《关于2025 年第一季度财务报告会计差错更正的议案》,同意公司按照《企业会计准则第28 号——会计政策、会计估计变更和差错更正》《公开发行证券的公司信息披露编报 规则第19号——财务信息的更正及相关披露》的相关规定和要求,对相关会计差错 进行更正。公司本次会计差错更正仅涉及2025年第一季度合并利润表,具体情况如 下: 一、会计差错更正情况 证券代码:300391 证券简称:*ST 长药 公告编号:2025-080 长江医药控股股份有限公司 关于2025年第一季度财务报告会计差错更正的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、误导性 陈述或重大遗漏。 特别提示: 1、本次会计差错更正影响长江医药控股股份有限公司(以下简称"公司") 2025年度第一季度合并利润表营业收入、营业总收入、营业成本、营业总成本,不 影响2025年第一季度合并资产负债表、合并现金流量表。 《企业会计准则第14号——收入》第三十四条:"企业应当 ...
*ST长药(300391) - 重大诉讼的进展公告
2025-08-06 09:34
证券代码:300391 证券简称:*ST长药 公告编号:2025-078 长江医药控股股份有限公司 重大诉讼的进展公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整,没有虚假记载、误导性 陈述或重大遗漏。 重要内容提示: 原告财通证券股份有限公司与被告长江医药控股股份有限公司、第三人湖北 长江大药房连锁有限公司债权人代位权纠纷案,十堰市郧阳区人民法院于2025年 4月10日立案。在诉讼过程中财通证券股份有限公司向十堰市郧阳区人民法院申 请财产保全,法院裁定冻结长江医药控股股份有限公司银行存款50,546,191.97 元或查封、扣押、冻结其同等价值的其他财产。本案涉案金额50,566,410.45元, 预计不会对公司当期损益产生影响。 一、诉讼事项受理的基本情况 2025年8月4日,长江医药控股股份有限公司(以下简称"公司"、"长药控 股")收到十堰市郧阳区人民法院送达的民事裁定书。十堰市郧阳区人民法院所 在地为湖北省十堰市郧阳区沿江大道26号。财通证券股份有限公司债权人代位权 纠纷案的诉讼各方当事人如下: 财通证券股份有限公司债权人代位权纠纷案的基本情况,详见公司于2025年 4月17日披露于巨潮 ...
*ST长药:股东盛世丰华累计被冻结股份约810万股
Mei Ri Jing Ji Xin Wen· 2025-07-29 16:37
Group 1 - The core point of the article is that *ST Changyao has announced that as of the disclosure date, shareholder Shengshi Fenghua has had approximately 8.1 million shares frozen [2] - For the fiscal year 2024, *ST Changyao's revenue composition is as follows: 57.19% from the photovoltaic industry and 42.81% from the pharmaceutical industry [2]
*ST长药(300391) - 关于控股股东部分股份冻结的公告
2025-07-29 08:22
证券代码:300391 证券简称:*ST长药 公告编号:2025-077 长江医药控股股份有限公司 关于控股股东部分股份冻结的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整,没有虚假记载、误导性 陈述或重大遗漏。 长江医药控股股份有限公司(以下简称"公司"、"长药控股"或"上市公 司")近日接到控股股东长兴盛世丰华商务有限公司(以下简称"盛世丰华") 的通知,盛世丰华持有的公司部分股份被冻结,具体事项如下: 一、股东股份被冻结的基本情况 | 股东 名称 | 是否为控股股东 或第一大股东及 | 本次冻结/标 记/拍卖等股 | 占其所持 | 占公司总 | 是否为限 售股及限 | | | 起始日 到期日 | | 冻结申请人 /拍卖人等 | 原因 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 股份比例 | 股本比例 | | | | | | | | | | 其一致行动人 | 份数量(股) | | | 售类型 | | | | | | | | 盛世 | 是 | 8,101,700 | 22 ...
*ST长药(300391) - 关于预重整第一次临时债权人会议和长江星等七家子公司实质合并重整案第一次债权人会议召开及表决结果的公告
2025-07-21 10:46
证券代码:300391 证券简称:*ST长药 公告编号:2025-076 出席本次会议的有表决权的债权人共 202 家,占有表决权的债权人总数的 99.51%。 二、会议表决情况 长江医药控股股份有限公司 关于预重整第一次临时债权人会议和长江星等七家子公司 实质合并重整案第一次债权人会议召开及表决结果的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整,没有虚假记载、误导性陈述 或重大遗漏。 长江医药控股股份有限公司(以下简称"公司""长药控股")于 2025 年 6 月 27 日在巨潮资讯网披露了《关于预重整第一次临时债权人会议和长江星等七家子公司实质 合并重整案第一次债权人会议提示性公告》,根据十堰市中级人民法院(以下简称"十 堰中院")(2024)鄂 03 破申 76 号《公告》,十堰中院于 2025 年 7 月 15 日上午 9:30 通过网络方式("小火鸟智慧破产平台"进行网络会议直播)召开长药控股预重整第一 次临时债权人会议。根据十堰中院(2025)鄂 03 破 1 号《公告》,十堰中院于 2025 年 7 月 15 日下午 14:30 通过网络方式("小火鸟智慧破产平台"进行网络会议直 ...
*ST长药: 关于预重整事项进展暨收到预重整延期批复的公告
Zheng Quan Zhi Xing· 2025-07-17 16:23
Core Viewpoint - The company, Changjiang Pharmaceutical Holdings Co., Ltd., has entered a pre-restructuring phase as decided by the Shiyan Intermediate People's Court, which has appointed a temporary administrator for the restructuring process [1][2]. Summary by Sections Pre-restructuring Basic Situation - The Shiyan Intermediate People's Court has initiated pre-restructuring for the company and appointed Shanghai Jintiancheng Law Firm as the temporary administrator [1]. Progress Situation - The pre-restructuring period has been extended by three months until October 20, 2025 [2]. - A series of announcements regarding the restructuring process have been made, including the recruitment of investors and the status of subsidiary restructuring [2]. Creditors' Meeting - The first creditors' meeting was held on time, covering various agenda items including the temporary administrator's report and the verification of creditor claims [3]. - Creditors participated in the meeting through an online voting platform, with a voting deadline set for July 18, 2025 [3]. Financial Condition - As of December 31, 2024, the company's consolidated financial statements show a net asset value of -432.84 million yuan and a net profit of -627.96 million yuan for the year [5]. - The company has experienced a significant decline in revenue, dropping from 1.615 billion yuan in 2022 to 112 million yuan in 2024 [5]. - The company is facing substantial overdue debts, with a total of 1.106 billion yuan in interest-bearing liabilities, and a high percentage of its bank accounts frozen [6][7]. Tax Obligations - The company’s subsidiary, Changjiang Star, has an outstanding tax obligation of 120 million yuan, which may affect its financial operations [7][8]. Information Disclosure - The company is committed to timely information disclosure regarding the restructuring process and has designated specific media outlets for announcements [8].
*ST长药(300391) - 关于预重整事项进展暨收到预重整延期批复的公告
2025-07-17 11:30
证券代码:300391 证券简称:*ST长药 公告编号: 2025-075 长江医药控股股份有限公司 关于预重整事项进展暨收到预重整延期批复的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整,没有虚假记载、误 导性陈述或重大遗漏。 一、预重整基本情况 2025年1月20日,长江医药控股股份有限公司(以下简称"公司"或"长药控股" )收到湖北省十堰市中级人民法院(下称"十堰中院")送达的《决定书》,十堰 中院决定对公司启动预重整,并指定上海市锦天城律师事务所担任公司预重整期间 的临时管理人。具体内容详见公司于2025年1月21日在巨潮资讯网披露的《关于法 院同意公司启动预重整程序并指定预重整临时管理人的公告》。 根据进展情况,公司于2025年1月23日在巨潮资讯网披露了《关于公司预重整 案债权申报的公告》、《关于临时管理人公开招募和遴选投资人的公告》;2025 年2月13日披露了《关于公司子公司被债权人申请重整的提示性公告》;2025年3 月14日披露了《关于法院裁定受理子公司重整并指定重整管理人的公告》;2025 年4月2日披露了《关于预重整事项的进展公告》;2025年4月15日披露了《关于预 重 ...
*ST长药: 第六届董事会第一次会议决议公告
Zheng Quan Zhi Xing· 2025-07-14 16:24
Group 1 - The board of directors of Changjiang Pharmaceutical Holdings Co., Ltd. held its first meeting of the sixth session on July 14, 2025, via on-site and remote voting methods due to urgency [1] - All 9 participating directors voted in favor of the proposals, resulting in a unanimous approval with no votes against or abstentions [2] - The meeting's procedures and methods complied with relevant laws, regulations, and the company's articles of association [1][2] Group 2 - The board's resolutions included the completion of the board's re-election and the appointment of senior management and securities representatives [2] - The proposals were reviewed and approved by the company's board nomination committee prior to the meeting [2]
*ST长药: 2025年第三次临时股东会决议公告
Zheng Quan Zhi Xing· 2025-07-14 16:24
Meeting Details - The meeting was held on July 14, 2025, with a total of 129 shareholders (or their representatives) attending, holding 39,039,250 shares, which accounts for 11.1434% of the total shares [1] - The meeting included both on-site attendance and online voting, with 127 shareholders participating through online voting, representing 3,615,550 shares [1] Voting Results - The voting results for the proposals were conducted through both on-site and online methods, with specific proposals receiving more than two-thirds approval from the attending shareholders [2][3] - The proposals included amendments to the company's articles of association and other governance documents, which were previously approved in board meetings [5][6] Legal Opinion - Hubei Yingda Law Firm provided a legal opinion confirming that the meeting's convening, attendance, and voting procedures complied with relevant laws and regulations, deeming the resolutions valid [6]